Dual-Stimuli Responsive Polymeric Micelles for the Effective Treatment of Rheumatoid Arthritis
Source abstract
Abstract
The nontargeted distribution and uncontrolled in vivo release of drugs impede their efficacy in the treatment of rheumatoid arthritis (RA). Delivering drugs to arthritic joints and releasing drugs on demand are a feasible solution to achieve the effective treatment of RA. In this paper, we report a facile method to assemble dual-stimuli responsive polymeric micelles from polyethylene glycol-phenylboric acid-triglycerol monostearate (PEG-PBA-TGMS, PPT) conjugates with the aim of delivering dexamethasone (Dex) to arthritic joints and controlling the release of Dex by inflammatory stimuli. We show that the release of Dex from the PPT micelles is accelerated in response to acidic pH and overexpressed matrix metalloproteinases. In an adjuvant-induced arthritis model, the PPT micelles preferentially accumulate in arthritic joints and show an excellent therapeutic efficacy after being intravenously administrated. Our results highlight the potential of the dual stimuli-responsive micelles as a promising therapeutic option for the effective treatment of inflammatory diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Rheumatoid Arthritis Research and Therapies · Advancements in Transdermal Drug Delivery · Orthopedic Infections and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Advanced Technologies of Materials, Ministry of Education and School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China
Advanced Materials Processing and Analysis Center and Department of Materials Science and Engineering, University of Central Florida, Florida 32816, United States
Funding
National Natural Science Foundation of China
References (48)
Show source-provided references
1. 10.1097/BOR.0b013e32832a2f0210.1097/BOR.0b013e32832a2f02 ↗
2. 10.1016/j.addr.2012.03.00610.1016/j.addr.2012.03.006 ↗
3. 10.1039/C7BM00254H10.1039/C7BM00254H ↗
4. 10.1038/nrd.2016.2110.1038/nrd.2016.21 ↗
5. 10.1038/nrdp.2018.110.1038/nrdp.2018.1 ↗
6. 10.1093/rheumatology/kes11510.1093/rheumatology/kes115 ↗
7. 10.1007/s12274-018-2233-310.1007/s12274-018-2233-3 ↗
8. 10.1038/nrrheum.2015.810.1038/nrrheum.2015.8 ↗
9. 10.2217/nnm.15.4510.2217/nnm.15.45 ↗
10. 10.3390/molecules2401014610.3390/molecules24010146 ↗
11. 10.1021/acsnano.9b0171010.1021/acsnano.9b01710 ↗
12. Andersson S. E. · J. Rheumatol. · 1999 · 26 · 2018
13. 10.1002/biot.20180002410.1002/biot.201800024 ↗
14. 10.1038/nrrheum.2016.6910.1038/nrrheum.2016.69 ↗
15. 10.1007/s00296-010-1592-110.1007/s00296-010-1592-1 ↗
16. 10.1016/j.bmc.2007.01.01110.1016/j.bmc.2007.01.011 ↗
17. 10.2174/138161282566619032110442410.2174/1381612825666190321104424 ↗
18. 10.1038/nmat377610.1038/nmat3776 ↗
19. 10.1002/adhm.20190028310.1002/adhm.201900283 ↗
20. 10.1021/acsabm.0c0088310.1021/acsabm.0c00883 ↗
21. 10.1016/j.ejps.2016.12.01110.1016/j.ejps.2016.12.011 ↗
22. 10.1016/j.jconrel.2019.12.02510.1016/j.jconrel.2019.12.025 ↗
23. 10.1016/j.jconrel.2020.09.04410.1016/j.jconrel.2020.09.044 ↗
24. 10.1016/j.jconrel.2016.12.02710.1016/j.jconrel.2016.12.027 ↗
25. 10.1038/natrevmats.2016.7510.1038/natrevmats.2016.75 ↗
26. 10.1021/acs.nanolett.9b0534010.1021/acs.nanolett.9b05340 ↗
27. 10.1002/art.3793210.1002/art.37932 ↗
28. 10.1016/j.actbio.2020.09.02610.1016/j.actbio.2020.09.026 ↗
29. 10.1016/j.ijpharm.2019.11862510.1016/j.ijpharm.2019.118625 ↗
30. 10.1038/s41467-018-03691-110.1038/s41467-018-03691-1 ↗
31. 10.1021/acsami.9b1713710.1021/acsami.9b17137 ↗
32. 10.1016/j.biopha.2016.03.00410.1016/j.biopha.2016.03.004 ↗
33. 10.1016/j.biomaterials.2020.12057410.1016/j.biomaterials.2020.120574 ↗
34. 10.1021/acsabm.0c0024210.1021/acsabm.0c00242 ↗
35. 10.1016/j.jconrel.2016.03.03510.1016/j.jconrel.2016.03.035 ↗
36. 10.1002/adma.20150631210.1002/adma.201506312 ↗
37. 10.1039/C4NR04796F10.1039/C4NR04796F ↗
38. 10.1016/j.biomaterials.2016.01.00810.1016/j.biomaterials.2016.01.008 ↗
39. 10.1002/mabi.20160013610.1002/mabi.201600136 ↗
40. 10.1016/j.ijpharm.2020.11978710.1016/j.ijpharm.2020.119787 ↗
41. 10.1016/j.carbpol.2019.11580310.1016/j.carbpol.2019.115803 ↗
42. 10.1039/C9RA08169K10.1039/C9RA08169K ↗
43. 10.1016/j.msec.2020.11125010.1016/j.msec.2020.111250 ↗
44. 10.1016/j.ajps.2020.07.00510.1016/j.ajps.2020.07.005 ↗
45. 10.1186/s12951-020-00604-710.1186/s12951-020-00604-7 ↗
46. 10.1002/art.2445310.1002/art.24453 ↗
47. 10.1038/nrrheum.2017.11510.1038/nrrheum.2017.115 ↗
48. 10.1080/10717544.2018.144705010.1080/10717544.2018.1447050 ↗